D. Boral Capital has begun coverage of Medicus Pharma (MDCX, Financial) with a Buy rating and set a price target of $14. Medicus Pharma, a biotechnology company in its development phase, is focusing on the commercialization of a novel, non-invasive treatment for basal cell carcinoma. This innovative approach utilizes a patented dissolvable microneedle array, which administers doxorubicin directly to tumor cells.
The research note highlights that Medicus Pharma presents an attractive opportunity for strategic buyers. The company offers a low-risk entry point into niche medical segments, with potential for platform expansion. Furthermore, potential investors can benefit from leveraging internal expertise in regulatory processes and commercialization strategies to accelerate value creation.
